Chronic Hepatitis B goes unnoticed and not diagnosed. It can be can be transmitted by any activity that involves exposure to blood and other body fluids. There is no cure, but treatment can slow the process down and help save liver functionality. BD
FOSTER CITY, Calif., Aug 11, 2008 (BUSINESS WIRE) -- Gilead Sciences, Inc. (GILD: Gilead Sciences Inc News, chart, profile, more Last: 56.43-0.34-0.60% 4:00pm 08/11/2008 Delayed quote data Add to portfolio Analyst Create alert Insider Discuss Financials Sponsored by: GILD 56.43, -0.34, -0.6%) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Viread(R) (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B, a serious liver disease caused by the hepatitis B virus (HBV). Chronic hepatitis B is the leading cause of liver cancer worldwide and affects an estimated two million individuals in the United States.
Around 7-8 per cent of the world’s population is estimated to be infected with
hepatitis B virus. It is mostly spread by blood and sexual transmission. In endemic areas, the carrier rate may be 10-20 per cent. It is often acquired at birth or in childhood, and is endemic in areas of Africa and Asia. Chronic hepatitis B virus carriers have a 100-fold greater chance of developing liver cancer than non-carriers.
aadautech, a cancer drug discovery and therapeutics blog